Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876662 · ClinicalTrials.gov registry record · Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 279
- Enrollment target
- 20
- Study locations
NCT06876662 is a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 279 participants, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06876662, a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 279 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Conditions Studied
Interventions
- DRUG Pirtobrutinib
Study Locations (20)
New York
- Cayuga Cancer Center - Ithaca
- Northwell Health - Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Florida Cancer Specialists - Sarasota
Other
- Flinders Medical Centre - Adelaide
- Peter MacCallum Cancer Centre - Melbourne
Georgia
- The Emory Clinic - Atlanta
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic- Minnesota - Rochester
Nebraska
- University Of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06876662
The ClinicalTrials.gov registry entry for NCT06876662 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (55% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06876662 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT06876662 about?
NCT06876662 is a clinical study titled "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma". Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stud...
What is the current status of trial NCT06876662?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 279 participants. The study started on 2025-05-20. Estimated completion is 2032-12.
What conditions does trial NCT06876662 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06876662?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06876662?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876662 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RECRUITING · Phase 4
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.